Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > GenScript antibody service guarantees ELISA titer of 1:20000 and positive western blot results

Abstract:
GenScript raises the quality standard for its antibody packages.

GenScript antibody service guarantees ELISA titer of 1:20000 and positive western blot results

PISCATAWAY, NJ | Posted on October 18th, 2008

International contract research organization (CRO) GenScript Corporation has renewed the guarantees for its custom antibody service packages. At present, GenScript guarantees positive Western blot for polyclonal and monoclonal antibody generated from qualified protein antigen and ELISA titer as high as 1:20000 or better for both standard and express polyclonal antibody generated using peptide antigen designed, synthesized and conjugated by GenScript.

GenScript guarantees the qualities of antibody for both of its polyclonal and monoclonal antibody production. "The renewed guarantees represent our technological advancement in antibody production." says Dr. Louis Liu, Director of the Antibody Department from GenScript. "The positive Western blot result is among the highest standard in the field. It makes GenScript stand out from its competitors." Many other biotech company's antibody guarantees does not mention western blot results.

Dr. Liu claims that this is possible because of GenScript's OptimumAntigenTM Design Tool, Nanotechnology for antigen preparation, and T-MaxTM Adjuvant. Specifically, GenScript's OptimumAntigenTM Design Tool takes the peptides' length, antigenicity, stability, cross-reactivity, terminus capping, and interactions with natural biological activities into account during the design process. GenScript antigen mixtures are processed down to nanoparticles to maximize immunization efficiency and boost immune response. In addition, GenScript's T-MaxTM adjuvant is significantly more potent in inducing the immune reaction than the standard Freund's adjuvant, which ensures high specificity and high titer of the produced antibodies.

Based on our historical records, at least 96.4% of the orders for which peptide antigens designed, synthesized and conjugated by GenScript received higher ELISA titer (≥1:32,000) than guaranteed. This builds up the confidence for GenScript to raise the bar of ELISA titer to 1:20000.

If the guarantee is unmet, GenScript will reinitiate the polyclonal antibody project free of charge. Meanwhile, GenScript monoclonal antibody production guarantees two positive clones for antibodies generated from both peptide antigen designed by GenScript and high quality protein antigen. In all cases, if GenScript's guarantees are unmet, GenScript will charge only set up fee for monoclonal antibody failures.

####

About GenScript Corporation
GenScript Corporation is a reliable outsourcing partner providing a wide array of services to augment all stages of the drug discovery and biological reagent manufacturing processes, including high-quality gene synthesis and cloning, custom protein expression and purification, custom peptide synthesis and antibody development, custom stable cell line development, and a wide selection of biological reagents to life science researchers in industrial and academic settings. GenScript Corporation is headquartered in Piscataway, New Jersey.

For more information, please click here

Contacts:
GenScript Corp. Logo
GenScript antibody service guarantees ELISA titer of 1:20000 and positive western blot results
GenScript raises the quality standard for its antibody packages.


FOR IMMEDIATE RELEASE
PRLog (Press Release) – Oct 16, 2008 – PISCATAWAY, N.J., – International contract research organization (CRO) GenScript Corporation has renewed the guarantees for its custom antibody service packages. At present, GenScript guarantees positive Western blot for polyclonal and monoclonal antibody generated from qualified protein antigen and ELISA titer as high as 1:20000 or better for both standard and express polyclonal antibody generated using peptide antigen designed, synthesized and conjugated by GenScript.

GenScript guarantees the qualities of antibody for both of its polyclonal and monoclonal antibody production. “The renewed guarantees represent our technological advancement in antibody production.” says Dr. Louis Liu, Director of the Antibody Department from GenScript. “The positive Western blot result is among the highest standard in the field. It makes GenScript stand out from its competitors.” Many other biotech company’s antibody guarantees does not mention western blot results.

Dr. Liu claims that this is possible because of GenScript’s OptimumAntigenTM Design Tool, Nanotechnology for antigen preparation, and T-MaxTM Adjuvant. Specifically, GenScript’s OptimumAntigenTM Design Tool takes the peptides’ length, antigenicity, stability, cross-reactivity, terminus capping, and interactions with natural biological activities into account during the design process. GenScript antigen mixtures are processed down to nanoparticles to maximize immunization efficiency and boost immune response. In addition, GenScript’s T-MaxTM adjuvant is significantly more potent in inducing the immune reaction than the standard Freund’s adjuvant, which ensures high specificity and high titer of the produced antibodies.

Based on our historical records, at least 96.4% of the orders for which peptide antigens designed, synthesized and conjugated by GenScript received higher ELISA titer (≥1:32,000) than guaranteed. This builds up the confidence for GenScript to raise the bar of ELISA titer to 1:20000.

If the guarantee is unmet, GenScript will reinitiate the polyclonal antibody project free of charge. Meanwhile, GenScript monoclonal antibody production guarantees two positive clones for antibodies generated from both peptide antigen designed by GenScript and high quality protein antigen. In all cases, if GenScript's guarantees are unmet, GenScript will charge only set up fee for monoclonal antibody failures.

GenScript Corporation is a reliable outsourcing partner providing a wide array of services to augment all stages of the drug discovery and biological reagent manufacturing processes, including high-quality gene synthesis and cloning, custom protein expression and purification, custom peptide synthesis and antibody development, custom stable cell line development, and a wide selection of biological reagents to life science researchers in industrial and academic settings. GenScript Corporation is headquartered in Piscataway, New Jersey.

# # #

For further information, please contact:
Sally Wang, Vice President
GENSCRIPT CORPORATION
1-(877) 436-7274

GenScript Corp.
120 Centennial Ave.
Piscataway,
NJ 08854
USA

Copyright © GenScript Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers develop artificial building blocks of life March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project